Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Troglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | MPC2 | O95563 | 2/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Troglitazone SCHEMBL4959 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL12496814 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL30050392 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL8496660 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL29349864 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL1536757 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL5672808 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL15888838 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL5672813 | 1.00 | MEN1 (0.64) | MEN1MAPTKMT2ATDP1CYP3A4 | |
| Troglitazone SCHEMBL3050513 | 0.99 | MEN1 (0.63) | MEN1MAPTKMT2ATDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4790 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119128420-A | Intelligent monitoring and early warning system for power distribution cabinet | 农毅 | 2024-12-13 | — | — | CN | claimed |
| US-12070461-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2024-08-27 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-11357777-B2 | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) | CYCLERION THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| US-20210361652-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | MELIOR PHARMACEUTICALS I, INC. | 2021-11-25 | — | — | US | claimed |
| CN-113225709-A | Relay strategy optimization method for assisting 5G NR Internet of vehicles communication at urban intersection | 广州航海学院 | 2021-08-06 | — | — | CN | claimed |
| US-11082824-B2 | Methods and devices for supporting transfer processes of data in wireless communications network | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2021-08-03 | — | — | US | claimed |
| US-11033548-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2021-06-15 | — | — | US | claimed |
| EP-3162163-B1 | METHODS AND DEVICES FOR SUPPORTING TRANSFER PROCESSES OF DATA IN WIRELESS COMMUNICATIONS NETWORK | ERICSSON TELEFON AB L M (SE) | 2020-04-01 | — | — | EP | claimed |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | claimed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | claimed |
| CN-1307561-A | Novel VLA-4 inhibitor: oMePUPA-V | BIOGEN INC (US) | 2001-08-08 | — | — | CN | claimed |
| WO-2001023387-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | claimed |
| WO-2001023388-A2 | AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | claimed |
| WO-2001023389-A2 | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES | NEUROGEN CORPORATION (US) | 2001-04-05 | — | — | WO | claimed |
| WO-2000066578-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | claimed |
| CN-1248243-A | Compounds | TAKARA SHUZO CO (JP) | 2000-03-22 | — | — | CN | claimed |
| CN-1202105-A | 2-alkylpyrrolidines | NOVO NORDISK AS (DK) | 1998-12-16 | — | — | CN | claimed |
| CN-1147939-A | Medicine for curing diabetes extracted from initial milk of cow | SHANGHAI INST OF PHYSIOLOGY CH (CN) | 1997-04-23 | — | — | CN | claimed |
| CN-2207197-Y | Heating medicinal band for diabetes | XING GUANGMING (CN) | 1995-09-13 | — | — | CN | claimed |